Substitutes for Nebaspor Ointment
Composition: Bacitracin 400IU + Polymyxin B 5000IU + Neomycin 3400IU
Nebaspor Ointment is out of stock right now
Good news — 6 medicines with the same composition are listed below and can be ordered instead.
You're viewing
Nebaspor Ointment
Intas Pharmaceuticals Ltd
₹35 Out of stock
View details Same composition & strength
5A like-for-like swap — identical active ingredients, same strength and form as Nebaspor Ointment.
Same molecule — other strengths or forms
1Same active ingredient(s) but a different strength or form — check the strength matches your prescription.
About these molecules
Bacitracin400IU
Full details →Polymyxin B5000IU
Full details →Polymyxin B is an antibiotic used to treat serious bacterial infections. It works by disrupting bacterial cell membranes. Polymyxin B's clinical relevance lies in its effectiveness against multidrug-resistant infections. In summary, Polymyxin B is a critical option for treating severe bacterial infections.
Neomycin3400IU
Full details →Neomycin is an aminoglycoside antibiotic used topically to treat bacterial infections of the skin. It works by inhibiting protein synthesis in bacteria, effectively stopping their growth and multiplication. Neomycin is commonly used for minor skin infections and is available in various topical formulations. Side effects may include localized irritation, but these are generally mild and transient. In summary, Neomycin is an effective topical antibiotic for treating skin infections.
Why a generic substitute?
Same active ingredient
A substitute has the exact same salt(s) — so it works the same way as the brand.
Often much cheaper
Generics can cost a fraction of the branded price for the identical molecule.
Quality-regulated
All medicines we list are from licensed sellers and meet the same standards.
Substitutes share the same active ingredients, but always confirm the strength and form with your doctor or pharmacist before switching — especially for chronic, prescription or narrow-therapeutic-index medicines.
